Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26607392 | 0.85 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL25201032 | 0.85 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL21335536 | 0.85 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL30325623 | 0.85 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2301080 | 0.85 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2082309 | 0.82 | KMT2A (0.35) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2082308 | 0.82 | KMT2A (0.35) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL8570166 | 0.82 | KMT2A (0.35) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL4671635 | 0.81 | KMT2A (0.38) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2082222 | 0.80 | PSEN1 (0.36) | MEN1MAPK1KMT2AGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-03-13 | — | — | US | disclosed |
| EP-4457217-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023129963-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3129372-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20080194547-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194547-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | MEN1 2925/4885MAPK1 189/4885KMT2A 923/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | MEN1 2925/4885MAPK1 189/4885KMT2A 923/4885 |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | MEN1 4216/4885MAPK1 2873/4885KMT2A 4067/4885 |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | MPO, NISCH, RPN2 | MEN1 4216/4885MAPK1 2873/4885KMT2A 4067/4885 |
| US-20080194547-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | MEN1 2542/4885MAPK1 3011/4885KMT2A 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.